These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 35476006)

  • 1. The COVID-19 Pandemic Rages on for People Who Are Immunocompromised.
    Rubin R
    JAMA; 2022 May; 327(19):1853-1855. PubMed ID: 35476006
    [No Abstract]   [Full Text] [Related]  

  • 2. COVID-19 in Immunocompromised Patients: A Systematic Review.
    Stainer A; Amati F; Suigo G; Simonetta E; Gramegna A; Voza A; Aliberti S
    Semin Respir Crit Care Med; 2021 Dec; 42(6):839-858. PubMed ID: 34918325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response to additional COVID-19 vaccine doses in people who are immunocompromised: a rapid review.
    Parker EPK; Desai S; Marti M; Nohynek H; Kaslow DC; Kochhar S; O'Brien KL; Hombach J; Wilder-Smith A
    Lancet Glob Health; 2022 Mar; 10(3):e326-e328. PubMed ID: 35180408
    [No Abstract]   [Full Text] [Related]  

  • 4. Long-Term Evolution of SARS-CoV-2 in an Immunocompromised Patient with Non-Hodgkin Lymphoma.
    Borges V; Isidro J; Cunha M; Cochicho D; Martins L; Banha L; Figueiredo M; Rebelo L; Trindade MC; Duarte S; Vieira L; Alves MJ; Costa I; Guiomar R; Santos M; Cortê-Real R; Dias A; Póvoas D; Cabo J; Figueiredo C; Manata MJ; Maltez F; Gomes da Silva M; Gomes JP
    mSphere; 2021 Aug; 6(4):e0024421. PubMed ID: 34319130
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NK cell frequencies, function and correlates to vaccine outcome in BNT162b2 mRNA anti-SARS-CoV-2 vaccinated healthy and immunocompromised individuals.
    Cuapio A; Boulouis C; Filipovic I; Wullimann D; Kammann T; Parrot T; Chen P; Akber M; Gao Y; Hammer Q; Strunz B; Pérez Potti A; Rivera Ballesteros O; Lange J; Muvva JR; Bergman P; Blennow O; Hansson L; Mielke S; Nowak P; Söderdahl G; Österborg A; Smith CIE; Bogdanovic G; Muschiol S; Hellgren F; Loré K; Sobkowiak MJ; Gabarrini G; Healy K; Sällberg Chen M; Alici E; Björkström NK; Buggert M; Ljungman P; Sandberg JK; Aleman S; Ljunggren HG
    Mol Med; 2022 Feb; 28(1):20. PubMed ID: 35135470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV and covid-19 in South Africa.
    Freer J; Mudaly V
    BMJ; 2022 Jan; 376():e069807. PubMed ID: 35086921
    [No Abstract]   [Full Text] [Related]  

  • 7. Audio Interview: Protecting the Immunocompromised from Covid-19.
    Rubin EJ; Baden LR; Morrissey S
    N Engl J Med; 2022 Jun; 386(23):e71. PubMed ID: 35675185
    [No Abstract]   [Full Text] [Related]  

  • 8. Effectiveness of 2-Dose Vaccination with mRNA COVID-19 Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults - Nine States, January-September 2021.
    Embi PJ; Levy ME; Naleway AL; Patel P; Gaglani M; Natarajan K; Dascomb K; Ong TC; Klein NP; Liao IC; Grannis SJ; Han J; Stenehjem E; Dunne MM; Lewis N; Irving SA; Rao S; McEvoy C; Bozio CH; Murthy K; Dixon BE; Grisel N; Yang DH; Goddard K; Kharbanda AB; Reynolds S; Raiyani C; Fadel WF; Arndorfer J; Rowley EA; Fireman B; Ferdinands J; Valvi NR; Ball SW; Zerbo O; Griggs EP; Mitchell PK; Porter RM; Kiduko SA; Blanton L; Zhuang Y; Steffens A; Reese SE; Olson N; Williams J; Dickerson M; McMorrow M; Schrag SJ; Verani JR; Fry AM; Azziz-Baumgartner E; Barron MA; Thompson MG; DeSilva MB
    MMWR Morb Mortal Wkly Rep; 2021 Nov; 70(44):1553-1559. PubMed ID: 34735426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunity to glycan α-Gal and possibilities for the control of COVID-19.
    la Fuente J; Gortázar C; Cabezas-Cruz A
    Immunotherapy; 2021 Feb; 13(3):185-188. PubMed ID: 33307805
    [No Abstract]   [Full Text] [Related]  

  • 10. Repurposing CD8
    Gujar S; Pol JG; Kim Y; Kroemer G
    Oncoimmunology; 2020 Jul; 9(1):1794424. PubMed ID: 32923158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective study into COVID-19-like symptoms in patients with and without immune-mediated inflammatory diseases or immunomodulating drugs.
    van Ouwerkerk L; van der Meulen-de Jong AE; Ninaber MK; Teng YKO; Huizinga TW; Allaart CF
    Ann Rheum Dis; 2021 Oct; 80(10):1364-1365. PubMed ID: 33849918
    [No Abstract]   [Full Text] [Related]  

  • 12. Immunology Lessons from the SARS-CoV-2 Pandemic.
    Yokoyama WM; Hogquist KA; O'Shea JJ
    Annu Rev Immunol; 2021 Apr; 39():v-vii. PubMed ID: 33939926
    [No Abstract]   [Full Text] [Related]  

  • 13. Telemedicine health disparities in oncology care.
    Wozniak AM; Rallis KS; Elkaddoum R
    Future Oncol; 2021 May; 17(14):1695-1698. PubMed ID: 33631991
    [No Abstract]   [Full Text] [Related]  

  • 14. Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.
    Charlton CL; Nguyen LT; Bailey A; Fenton J; Plitt SS; Marohn C; Lau C; Hinshaw D; Lutsiak C; Simmonds K; Kanji JN; Zelyas N; Lee N; Mengel M; Tipples G
    Microbiol Spectr; 2021 Sep; 9(1):e0029121. PubMed ID: 34406813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What is the immunological response to BNT162b2 mRNA vaccine in immunocompromised patients?
    Silvestris N
    EBioMedicine; 2021 Dec; 74():103733. PubMed ID: 34864362
    [No Abstract]   [Full Text] [Related]  

  • 16. Common Variable Immunodeficiency Disorders as a Model for Assessing COVID-19 Vaccine Responses in Immunocompromised Patients.
    Ameratunga R; Woon ST; Steele R; Lehnert K; Leung E; Edwards ESJ; Brooks AES
    Front Immunol; 2021; 12():798389. PubMed ID: 35116031
    [No Abstract]   [Full Text] [Related]  

  • 17. The Impact of the SARS-CoV-2 Pandemic in PID Patients Receiving Ig Replacement Therapy.
    Cekic S; Cicek F; Kilic SS
    J Clin Immunol; 2021 May; 41(4):733-737. PubMed ID: 33452597
    [No Abstract]   [Full Text] [Related]  

  • 18. Vaccine-induced protection in aging adults and pandemic response.
    Schenkelberg T
    Biochem Biophys Res Commun; 2021 Jan; 538():218-220. PubMed ID: 33213845
    [No Abstract]   [Full Text] [Related]  

  • 19. SARS-CoV-2 infection in fully vaccinated patients with multiple myeloma.
    Sgherza N; Curci P; Rizzi R; Attolico I; Loconsole D; Mestice A; Chironna M; Musto P
    Blood Cancer J; 2021 Dec; 11(12):201. PubMed ID: 34907155
    [No Abstract]   [Full Text] [Related]  

  • 20. The emergence of SARS-CoV-2 variants threatens to decrease the efficacy of neutralizing antibodies and vaccines.
    Murano K; Guo Y; Siomi H
    Biochem Soc Trans; 2021 Dec; 49(6):2879-2890. PubMed ID: 34854887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.